← FDA DRUG APPROVALS

FDA NDA · NDA022517

NOCDURNA

Sponsor: FERRING PHARMS INC

APPLICATION
NDA022517
TYPE
NDA
ORIGINAL APPROVAL
2018-06-21
LATEST ACTION
2018-06-21
ROUTE
SUBLINGUAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

NOCDURNA · ReferenceDiscontinued
DESMOPRESSIN ACETATE 0.0553MG · TABLET · SUBLINGUAL
NOCDURNA · ReferenceDiscontinued
DESMOPRESSIN ACETATE 0.0277MG · TABLET · SUBLINGUAL

Approval history

2018-06-21Type 5 - New Formulation or New Manufacturer · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →